Stoke Therapeutics, Inc.
DE ˙ DB ˙ US86150R1077
24,23 € ↓ -1,44 (-5,61%)
2026-06-03
AKTIENPREIS
SecurityDE:0GT / Stoke Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership2,276,512 shares
Latest Disclosed Value $ 74,123,231
State Street Corp reports 8.87% decrease in ownership of 0GT / Stoke Therapeutics, Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 2,276,512 shares of Stoke Therapeutics, Inc. (DE:0GT) valued at $62,376,429 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 2,498,049 shares of Stoke Therapeutics, Inc.. This represents a change in shares of -8.87% during the quarter. The current value of the position is $55,159,886 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F STOKE THERAPEUTICS COM 86150R107 2,276,512 -221,537 -8.87 74,123 -6.51 0.0026
2026-02-13 2025-12-31 13F STOKE THERAPEUTICS COM 86150R107 2,498,049 1,072,176 75.19 79,288 136.62 0.0027
2025-11-14 2025-09-30 13F STOKE THERAPEUTICS COM 86150R107 1,425,873 -61,283 -4.12 33,508 98.52 0.0012
2025-08-14 2025-06-30 13F STOKE THERAPEUTICS COM 86150R107 1,487,156 -88,127 -5.59 16,879 61.14 0.0006
2025-05-15 2025-03-31 13F STOKE THERAPEUTICS COM 86150R107 1,575,283 -12,380 -0.78 10,476 -40.18 0.0004
2025-02-14 2024-12-31 13F STOKE THERAPEUTICS COM 86150R107 1,587,663 -141,225 -8.17 17,512 -17.59 0.0007
2024-11-14 2024-09-30 13F STOKE THERAPEUTICS COM 86150R107 1,728,888 137,145 8.62 21,248 -1.19 0.0009
2024-08-14 2024-06-30 13F STOKE THERAPEUTICS COM 86150R107 1,591,743 1,012,136 174.62 21,504 174.85 0.0009
2024-05-15 2024-03-31 13F STOKE THERAPEUTICS COM 86150R107 579,607 36,074 6.64 7,825 173.76 0.0003
2024-02-14 2023-12-31 13F STOKE THERAPEUTICS COM 86150R107 543,533 -42,475 -7.25 2,859 23.83 0.0001
2023-11-14 2023-09-30 13F STOKE THERAPEUTICS COM 86150R107 586,008 34,326 6.22 2,309 -60.64 0.0001
2023-08-14 2023-06-30 13F STOKE THERAPEUTICS COM 86150R107 551,682 130,054 30.85 5,864 66.97 0.0003
2023-05-15 2023-03-31 13F STOKE THERAPEUTICS COM 86150R107 421,628 7,879 1.90 3,512 -8.01 0.0002
2023-05-15 2022-12-31 13F/A-99 STOKE THERAPEUTICS COM 86150R107 413,749 2,259 0.55 3,819 -27.74 0.0002
2023-05-15 2022-12-31 13F STOKE THERAPEUTICS COM 86150R107 413,749 2,259 3,819 0.0002
2022-11-15 2022-09-30 13F STOKE THERAPEUTICS COM 86150R107 411,490 29,384 7.69 5,284 4.68 0.0003
2022-08-15 2022-06-30 13F STOKE THERAPEUTICS COM 86150R107 382,106 -571,919 -59.95 5,048 -74.86 0.0003
2022-05-16 2022-03-31 13F STOKE THERAPEUTICS COM 86150R107 954,025 157,173 19.72 20,082 5.05 0.0010
2022-02-14 2021-12-31 13F STOKE THERAPEUTICS COM 86150R107 796,852 -117,819 -12.88 19,116 -17.85 0.0009
2021-11-15 2021-09-30 13F STOKE THERAPEUTICS COM 86150R107 914,671 9,835 1.09 23,269 -23.60 0.0012
2021-08-16 2021-06-30 13F STOKE THERAPEUTICS COM 86150R107 904,836 157,548 21.08 30,457 4.93 0.0016
2021-07-09 2021-03-31 13F/A-1 STOKE THERAPEUTICS COM 86150R107 747,288 313,180 72.14 29,025 7.96 0.0017
2021-05-17 2021-03-31 13F STOKE THERAPEUTICS COM 86150R107 747,288 313,180 29,025 0.0017
2021-02-16 2020-12-31 13F STOKE THERAPEUTICS COM 86150R107 434,108 204,696 89.23 26,884 249.92 0.0016
2020-11-10 2020-09-30 13F STOKE THERAPEUTICS COM 86150R107 229,412 -37,727 -14.12 7,683 20.69 0.0005
2020-08-14 2020-06-30 13F STOKE THERAPEUTICS COM 86150R107 267,139 -27,142 -9.22 6,366 -5.53 0.0005
2020-06-19 2020-03-31 13F/A-1 STOKE THERAPEUTICS COM 86150R107 294,281 124,537 73.37 6,739 40.19 0.0006
2020-05-11 2020-03-31 13F STOKE THERAPEUTICS COM 86150R107 294,281 124,537 6,739 591.8199
2020-02-06 2019-12-31 13F STOKE THERAPEUTICS COM 86150R107 169,744 30,765 22.14 4,807 60.93 0.0003
2019-11-14 2019-09-30 13F STOKE THERAPEUTICS COM 86150R107 138,979 138,979 2,987 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.